Interview with Laura Campo, MOPEAD project leader, International Corporate Affairs, Alzheimer’s disease at Eli Lilly and Company.
Why is EARLY diagnosis of Alzheimer’s disease (AD) important?
The current academic understanding of Alzheimer’s disease (AD) pathogenesis and management emphasizes the need for an early detection. In clinical practice, diagnosis is still occurring late in the disease process, at a stage when neurological decline may not be slowed, stopped or reversed. An early AD diagnosis may offer the best opportunity to give people more time to do the things that matter to them, including considering a clinical trial as part of their personal plan.
We need to better understand the obstacles to engagement for early diagnosis and treatment, and find successful strategies to overcome them. This will provide information on how to improve the consistency of diagnosis and communication as soon as symptoms begin, for earlier identification and care, support, referrals and, where possible, provide opportunities for those diagnosed to participate in clinical trials.
How does MOPEAD promote cooperation between researchers, clinicians, industries and patients?
MOPEAD brings together a number of private- and public-sector organizations, the non-profit community and academia with the common aspiration to bring value to people living with Alzheimer’s disease, their carers and the healthcare system. A great network of clinical centers and their referential GP outpatient clinics, along with the invaluable expertise for data management, online strategies and communication, well serves MOPEAD’s objective to encourage a cultural shift toward making a timely diagnosis of AD at the initial symptomatic stages.
Under the IMI auspice, MOPEAD fosters the interconnection with other key research projects that are tackling AD across its continuum (i.e. EPAD or ROADMAP), providing a breadth of knowledge and insight to the whole AD community.
What are the benefits of MOPEAD for the research community?
MOPEAD will explore different strategies to detect hidden cases of cognitive impairment. MOPEAD will also respond to the urgency of finding interventions to halt AD by stimulating a faster involvement in clinical trials, bringing value not only to the research community, but also to society as a whole, healthcare systems and industry.